美国新生儿COVID-19流行病学特征
基于美国109个医疗系统超100万次新生儿就诊数据,COVID-19发病率为91.1/10万次就诊(95%CI 85.3-97.2),其中7.7%为重症。大多数新生儿无症状或轻症,无需呼吸支持,但重症者需呼吸支持及药物治疗,1例死亡。
要点
- 新生儿COVID-19发病率约91.1/10万次就诊,重症率7/10万次就诊。
- 常见表现为呼吸急促和发热,重症者更需呼吸支持(50.7% vs 5.2%)。
- 大多数新生儿无症状或轻症,但少数可发展为重症甚至死亡。
核心结论
- 大多数感染SARS-CoV-2的新生儿无症状或表现为轻度疾病,无需呼吸支持。
- 部分新生儿可出现重症,需使用瑞德西韦和COVID-19恢复期血浆治疗。
- 新生儿SARS-CoV-2感染虽罕见,但可能导致严重疾病甚至死亡。
研究设计与样本
- 回顾性队列研究,数据来自2020年3月至2021年2月美国109个医疗系统的Cerner Real World数据库,纳入超过100万次新生儿就诊。
- 通过SARS-CoV-2实验室检测和诊断代码评估COVID-19诊断,计算每10万次就诊的发病率。
主要发现
- 918名新生儿(0.1%)诊断为COVID-19,发病率为91.1/10万次就诊(95%CI 85.3-97.2)。
- 其中71例(7.7%)为重症感染,重症发病率为7/10万次就诊(95%CI 5.5-8.9)。
- 诊断中位时间为出生后14.5天(四分位距3.1-24.2天)。
- 常见感染体征为呼吸急促和发热。
- 重症新生儿更可能接受呼吸支持(50.7% vs 5.2%,P < .001)。
关键数值与推荐
- 重症新生儿接受镇痛药(38%)、抗生素(33.8%)、抗凝药(32.4%)、糖皮质激素(26.8%)、瑞德西韦(2.8%)和COVID-19恢复期血浆(1.4%)。
- 93.6%的新生儿经治疗后出院回家,1.1%转至其他医院,5.2%出院去向未知。
- 1例新生儿(0.1%)表现为儿童多系统炎症综合征(MIS-C)疑似症状,住院11天后死亡。
临床怎么用
- 新生儿COVID-19总体预后良好,多数无需呼吸支持,但需警惕少数重症可能。
- 对出现呼吸急促或发热的新生儿,应考虑SARS-CoV-2检测。
- 重症新生儿可能需要呼吸支持及特定治疗,如瑞德西韦或恢复期血浆。
局限性
- 数据来源于特定数据库,可能存在编码不完整或误分类。
- 回顾性设计可能遗漏无症状病例或导致诊断延迟。
- 出院去向未知的病例可能影响结局评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Data on coronavirus disease 2019 (COVID-19) infections in neonates are limited. We aimed to identify and describe the incidence, presentation, and clinical outcomes of neonatal COVID-19. METHODS: Over 1 million neonatal encounters at 109 United States health systems, from March 2020 to February 2021, were extracted from the Cerner Real World Database. COVID-19 diagnosis was assessed using severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) laboratory tests and diagnosis codes. Incidence of COVID-19 per 100 000 encounters was estimated. RESULTS: COVID-19 was diagnosed in 918 (0.1%) neonates (91.1 per 100 000 encounters [95% confidence interval 85.3-97.2]). Of these, 71 (7.7%) had severe infection (7 per 100 000 [95% confidence interval 5.5-8.9]). Median time to diagnosis was 14.5 days from birth (interquartile range 3.1-24.2). Common signs of infection were tachypnea and fever. Those with severe infection were more likely to receive respiratory support (50.7% vs 5.2%, P < .001). Severely ill neonates received analgesia (38%), antibiotics (33.8%), anticoagulants (32.4%), corticosteroids (26.8%), remdesivir (2.8%), and COVID-19 convalescent plasma (1.4%). A total of 93.6% neonates were discharged home after care, 1.1% were transferred to another hospital, and discharge disposition was unknown for 5.2%. One neonate (0.1%) with presentation suggestive of multisystem inflammatory syndrome in children died after 11 days of hospitalization. CONCLUSIONS: Most neonates infected with SARS-CoV-2 were asymptomatic or developed mild illness without need for respiratory support. Some had severe illness requiring treatment of COVID-19 with remdesivir and COVID-19 convalescent plasma. SARS-CoV-2 infection in neonates, though rare, may result in severe disease.
引用
- Devin J, Marano R, Mikhael M, et al. Epidemiology of Neonatal COVID-19 in the United States. Pediatrics. 2022. PMID: 35996224. doi:10.1542/peds.2022-056297
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。